Amphetamine News and Research RSS Feed - Amphetamine News and Research

Combination of two environmental factors contributes to schizophrenia

Combination of two environmental factors contributes to schizophrenia

The interplay between an infection during pregnancy and stress in puberty plays a key role in the development of schizophrenia, as behaviourists from ETH Zurich demonstrate in a mouse model. However, there is no need to panic. [More]
Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine continue to drop in the UK

Annual deaths related to heroin and morphine are continuing to drop significantly, falling from 41 per cent of total drug-related deaths in the UK in 2010 to 32 per cent in 2011. Meanwhile, deaths from 'legal highs' - some of which have now been banned - remained steady following a large increase in the previous year. [More]
Modafinil may help some people to reduce drinking by improving their impulse control

Modafinil may help some people to reduce drinking by improving their impulse control

Poor impulse control contributes to one's inability to control the consumption of rewarding substances, like food, alcohol, and other drugs. This can lead to the development of addiction. FDA-approved medications for alcoholism, like naltrexone (Revia) and disulfiram (Antabuse), are thought to reduce alcohol consumption by curbing cravings and creating unpleasant reactions to alcohol, effects which reduce the desire to drink alcohol. [More]
Social isolation increases risk of addiction to amphetamine and alcohol

Social isolation increases risk of addiction to amphetamine and alcohol

Rats that are socially isolated during a critical period of adolescence are more vulnerable to addiction to amphetamine and alcohol, found researchers at The University of Texas at Austin. Amphetamine addiction is also harder to extinguish in the socially isolated rats. [More]
NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

NIDA's 2012 Monitoring the Future survey shows rates stable or down for most drugs

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms was revealed in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan. [More]

Combination of mixed amphetamine salts and topiramate shows promise for cocaine dependence

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition. [More]
MH6 vaccine shows promise in treating meth addiction

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication. [More]
Exendin-4 could effectively treat addiction

Exendin-4 could effectively treat addiction

Vanderbilt researchers are reporting today that a drug currently used to treat type 2 diabetes could be just as effective in treating addiction to drugs, including cocaine. [More]
Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone and memory loss: an interview with Craig Motbey

Mephedrone is a fairly new designer drug which has been around for a few years. It exploded in popularity in Europe (and particularly in the UK) before it started to spread in a major way elsewhere. [More]

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies. [More]

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD. [More]
Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED). [More]

Scientists analyze raw sewage samples to determine illicit drug use

Surveys of drug use form an important basis for the development of effective drug policies, and also for measuring the effectiveness of existing policies. For the first time in history, scientists have now made direct comparisons of illicit drug use in 19 European cities by a cooperative analysis of raw sewage samples. [More]
Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising levels of the neurotransmitter dopamine in the frontal cortex of the brain significantly decreased impulsivity in healthy adults, in a study conducted by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco. [More]
HIV in MSM increasing in countries of all incomes

HIV in MSM increasing in countries of all incomes

A new Lancet Series published to coincide with the AIDS2012 meeting highlights a population where the HIV epidemic is growing in countries of all incomes: men who have sex with men (MSM). The first paper in the Series charts the epidemiology of HIV among MSM, and is by Professor Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, and colleagues. [More]
ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP). [More]

FDA approves Actavis Mixed Amphetamine Salts ER Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg. [More]

Longer looks: Battling HIV in Washington; Adderall use among U.S. high schoolers

On a recent day not far from Capitol Hill and the White House, about a dozen HIV outreach workers toting bright yellow duffle bags stuffed with condoms and prevention information stood outside of the Anacostia Metro station. ... After a couple of hours, they had handed out hundreds of packs of condoms -- and had persuaded 21 people to take an HIV test with an oral swab in a Chevy van parked nearby. "You have to know your status, man. I'd rather be safe than sorry," said Alvern Harris, 25, as he waited for his results. [More]
Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties." [More]
Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder. [More]